|
ABOUT DATAMONITOR HEALTHCARE
- About the CNS pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the migraine market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Disease overview
- Etiology
- Epidemiology
- Segmentation of migraine
- Current market situation
- Strategic scoping and focus
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the migraine market
- Global opportunities and threats
- US: opportunities and threats
- Market overview
- Opportunities
- Threats
- Japan: opportunities and threats
- Market overview
- Opportunities
- Threats
- France: opportunities and threats
- Market overview
- Opportunities
- Threats
- Germany: opportunities and threats
- Market overview
- Opportunities
- Threats
- Italy: opportunities and threats
- Market overview
- Opportunities
- Threats
- Spain: opportunities and threats
- Market overview
- Opportunities
- Threats
- UK: opportunities and threats
- Market overview
- Opportunities
- Threats
CHAPTER 4 FORECAST ANALYSIS
- Factors affecting the market
- Topamax approved for migraine prophylaxis in the US
- Generic Topamax enters US market
- Forecasting assumptions and events
- 2004
- Frovatriptan launched in Italy
- 2005
- Zolmitriptan nasal spray launch in Japan
- 2006
- Frovatriptan gains approval for MAM
- MT-400 (Trexima) launched
- 2007
- Launch of donitriptan
- GSK/Aradigms needleless formulation of sumatriptan launched
- 2008
- Naratriptan launched in Japan
- Nimodipine launched
- Olcegepant launched in first market
- 2009
- Launch of almotriptan in Japan
- Generic sumatriptan enters US market
- Arius/Atrixs transmucosal formulation of sumatriptan launched
- 2010
- Naratriptan US patent expiry
- NovaDels sublingual sumatriptan formulation launched
- 2012
- Rizatriptan and frovatriptan US patent expiries
- 2013
- Zolmitriptan and eletriptan US patent expiries
- Limitations of data
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Case study: Sumatriptan patent expiry-GSKs strategic options
- Introduction
- GSKs current position in the migraine market
- The strategic challenge-facing the threat of patent expiry
- Patent expiry is not a new challenge for GSK
- Augmentin
- Wellbutrin
- Paxil
- Summary of GSKs previous patent expiry management strategies
- GSKs current and future activities to manage the threat of
sumatriptan generic erosion
- Imitrex reformulation
- Novel indication for Imitrex
- Launching a replacement drug
- Refocus on alternative oral triptan for migraine
- Inhalation delivery-a potential additional opportunity for GSK?
- Summary
- Case study: Promoting migraine prophylaxis
- Current treatments
- Anticonvulsants
- Antidepressants
- Beta-blockers
- Serotonergic agents
- Others
- Unmet needs
- Greater efficacy
- Fewer side effects
- Migraine-specific drug
- Use of triptans for prophylaxis
- Datamonitor recommendations
APPENDIX A-MARKET DATA AND MAJOR BRAND KEY FACTS
- Global migraine market data
- Triptans market data
APPENDIX B
- Contributing experts
- Bibliography
- Epidemiology
- Clinical trial data
- Websites
- Report methodology
- Standard units
- Japanese market data
- Regional launch dates for new products
- Additional information
- About Datamonitor
- About Datamonitor Healthcare
- About the CNS analysis team
- Key therapy team members
- Lynda Lynch, Director CNS
- David Abramson, Therapeutic Lead Consultant
- Disclaimer
- List of Tables
- Table 1: Prevalence of migraine in the seven major markets
- Table 2: Key triptan brands
- Table 3: Other acute migraine drugs
- Table 4: Key brands in migraine prophylaxis
- Table 5: The US migraine market sales and share
- Table 6: The Japanese migraine market sales and share
- Table 7: The French migraine market sales and share
- Table 8: The German migraine market sales and share
- Table 9: The Italian migraine market sales and shares
- Table 10: The Spanish migraine market sales and share
- Table 11: The UK migraine market sales and share
- Table 12: Comparative action across triptan brands
- Table 13: Historical sales of the leading migraine drugs ($m),
2000-03*
- Table 14: Sumatriptan: key facts
- Table 15: Naratriptan: key facts
- Table 16: Zolmitriptan: key facts
- Table 17: Rizatriptan: key facts
- Table 18: Almotriptan: key facts
- Table 19: Eletriptan: key facts
- Table 20: Frovatriptan: key facts
- List of Figures
- Figure 1: Summary of global opportunities for the migraine market and
examples of influencing strengths/weaknesses
- Figure 2: Summary of global threats for the migraine market and
examples of influencing strengths/weaknesses
- Figure 3: Summary of opportunities in the US migraine market and
examples of influencing strengths/weaknesses
- Figure 4: Summary of threats in the US migraine market and examples of
influencing strengths/weaknesses
- Figure 5: Summary of opportunities in the Japanese migraine market and
examples of influencing strengths/weaknesses
- Figure 6: Summary of threats in the Japanese migraine market and
examples of influencing strengths/weaknesses
- Figure 7: Summary of opportunities in the French migraine market and
examples of influencing strengths/weaknesses
- Figure 8: Summary of threats in the French migraine market and
examples of influencing strengths/weaknesses
- Figure 9: Summary of opportunities in the German migraine market and
examples of influencing strengths/weaknesses
- Figure 10: Summary of threats in the German migraine market and
examples of influencing strengths/weaknesses
- Figure 11: Summary of opportunities in the Italian migraine market and
examples of influencing strengths/weaknesses
- Figure 12: Summary of threats in the Italian migraine market and
examples of influencing strengths/weaknesses
- Figure 13: Summary of opportunities in the Spanish migraine market and
examples of influencing strengths/weaknesses
- Figure 14: Summary of threats in the Spanish migraine market and
examples of influencing strengths/weaknesses
- Figure 15: Summary of opportunities in the UK migraine market and
examples of influencing strengths/weaknesses
- Figure 16: Summary of threats in the UK migraine market and examples
of influencing strengths/weaknesses
| 
View Cart
